ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2436

The Impact of Different Classes of Lupus Nephritis on Maternal and Fetal Outcomes

Bruna Costa Rodrigues1, Marcela Ignacchiti Lacerda1, Guilherme Ramires de Jesus2, Flavia Cunha dos Santos2, Nilson Ramires de Jesus2, Roger Abramino Levy1,3 and Evandro Mendes Klumb1, 1Rheumatology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, 2Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, 3Immunology and Inflammation, GlaxoSmithKline, Upper Providence, PA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Lupus nephritis, nephritis and pregnancy, SLE

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Reproductive Issues in Rheumatic Disorders Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: During pregnancy, history of lupus nephritis (LN) has been independently associated with increased risk of adverse maternal and fetal outcomes, which are even more frequent when LN is active at conception. The objective of this study was to analyze the impact of different classes of lupus nephritis (LN) as risk variables for maternal and fetal adverse outcomes in a cohort of pregnant lupus patients.

Methods: 146 pregnancies of 136 SLE patients (ACR criteria) were included. Maternal adverse outcomes observed for each nephritis class among LN patients were compared with those without nephritis. Demographic and clinical features of SLE were recorded, including maternal age at delivery, parity and ethnicity, years since the diagnosis of SLE, activity at conception, association with antiphospholipid syndrome, systemic arterial hypertension and permanent damage defined by SLICC/ACR damage index (SDI). Fischer exact test was used for categorized variables and Student’s t test was used for the continuous variables.

Results: 54 patients had proliferative LN (classes III and IV), 12 had mesangial or membranous LN (classes II and V) and 80 did not have LN.  SLE patients with proliferative LN but not those with classes II and V had more frequently SLE activity at conception (p=0.02), flares (p=0.04) or continuous active disease during pregnancy and puerperium (p=0.006), hospitalization for any cause (p=0.003) and due to SLE (p=0.02) and preeclampsia (p=0.05) than patients without nephritis. When classes II and V LN were compared to patients without LN, there were no statistically significant differences in the main outcomes measured. SDI ≥ 1 was more frequent in classes III and IV than among the other patients, even when renal scores were not included. Adverse fetal outcomes such as prematurity, small for gestational age newborns, admission to NICU and perinatal death were more frequent in patients with proliferative LN (61% vs 42.5%; p=0.01), but not with mesangial and membranous LN (41.6% vs 42.5%; p=0.60) when compared to lupus patients without LN.

Conclusion: SLE patients with proliferative nephritis (classes III and IV), but not with classes II or V, have a higher frequency of adverse maternal and fetal outcomes. This is probably due to the major impact of proliferative forms of nephritis on women global heath, which is corroborated by the higher SDI found. These findings suggest that further LN classification beyond the common term nephritis in the context of lupus pregnancy as the impact on maternal and fetal outcomes varies according to histological classes.


Disclosure: B. Costa Rodrigues, None; M. Ignacchiti Lacerda, None; G. Ramires de Jesus, None; F. C. dos Santos, None; N. Ramires de Jesus, None; R. A. Levy, GlaxoSmithKline, 3; E. M. Klumb, None.

To cite this abstract in AMA style:

Costa Rodrigues B, Ignacchiti Lacerda M, Ramires de Jesus G, dos Santos FC, Ramires de Jesus N, Levy RA, Klumb EM. The Impact of Different Classes of Lupus Nephritis on Maternal and Fetal Outcomes [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/the-impact-of-different-classes-of-lupus-nephritis-on-maternal-and-fetal-outcomes/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-impact-of-different-classes-of-lupus-nephritis-on-maternal-and-fetal-outcomes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology